Lexeo Therapeutics, Inc. Research and Development Expense
Lexeo Therapeutics, Inc. (LXEO) reported Research and Development Expense of $19.03 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12
- Lexeo Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $19.03M, a 29.25% increase year-over-year.
- Lexeo Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $15.70M, a 8.55% decline year-over-year.
- Lexeo Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $16.21M, a 11.74% decline year-over-year.
- Lexeo Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $15.70M, a 32.99% decline year-over-year.
- Lexeo Therapeutics, Inc. research and development expense for fiscal 2025 was $63.80M, a 13.89% decline from fiscal 2024.
- Lexeo Therapeutics, Inc. research and development expense for fiscal 2024 was $74.09M, a 39.45% increase from fiscal 2023.
- Lexeo Therapeutics, Inc. research and development expense for fiscal 2023 was $53.13M, a 8.07% increase from fiscal 2022.
- Lexeo Therapeutics, Inc. research and development expense for fiscal 2022 was $49.16M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $19.03M 10-Q · filed 2026-08-12 | $34.73M 10-Q · filed 2026-08-12 | $50.94M derived: sum of 3 quarters · filed 2026-08-12 | $66.64M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $15.70M 10-Q · filed 2026-05-11 | $31.91M derived: sum of 2 quarters · filed 2026-05-11 | $47.61M derived: sum of 3 quarters · filed 2026-05-11 | $62.33M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $16.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $31.91M derived: sum of 2 quarters · filed 2026-03-30 | $46.63M derived: sum of 3 quarters · filed 2026-08-12 | $63.80M 10-K · filed 2026-03-30 |
| 2025-09-30 | $15.70M 10-Q · filed 2025-11-05 | $30.42M derived: sum of 2 quarters · filed 2026-08-12 | $47.59M 10-Q · filed 2025-11-05 | $65.95M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $14.72M 10-Q · filed 2026-08-12 | $31.89M 10-Q · filed 2026-08-12 | $50.26M derived: sum of 3 quarters · filed 2026-08-12 | $73.68M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $17.17M 10-Q · filed 2026-05-11 | $35.54M derived: sum of 2 quarters · filed 2026-05-11 | $58.96M derived: sum of 3 quarters · filed 2026-05-11 | $75.52M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $18.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $41.79M derived: sum of 2 quarters · filed 2026-03-30 | $58.35M derived: sum of 3 quarters · filed 2026-03-30 | $74.09M 10-K · filed 2026-03-30 |
| 2024-09-30 | $23.42M 10-Q · filed 2025-11-05 | $39.98M derived: sum of 2 quarters · filed 2025-11-05 | $55.73M 10-Q · filed 2025-11-05 | $63.94M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $16.56M 10-Q · filed 2025-08-14 | $32.30M 10-Q · filed 2025-08-14 | $40.51M derived: sum of 3 quarters · filed 2025-08-14 | $57.76M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $15.74M 10-Q · filed 2025-05-12 | $23.95M derived: sum of 2 quarters · filed 2025-05-12 | $41.20M derived: sum of 3 quarters · filed 2025-05-12 | $52.43M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $8.21M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $25.46M derived: sum of 2 quarters · filed 2025-03-24 | $36.69M derived: sum of 3 quarters · filed 2025-03-24 | $53.13M 10-K · filed 2025-03-24 |
| 2023-09-30 | $17.25M 10-Q · filed 2024-11-13 | $28.48M derived: sum of 2 quarters · filed 2024-11-13 | $44.92M 10-Q · filed 2024-11-13 | $56.31M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $11.24M 10-Q · filed 2024-08-12 | $27.67M 10-Q · filed 2024-08-12 | $39.06M derived: sum of 3 quarters · filed 2024-08-12 | $54.42M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $16.44M 10-Q · filed 2024-05-09 | $27.82M derived: sum of 2 quarters · filed 2024-05-09 | $43.19M derived: sum of 3 quarters · filed 2024-05-09 | |
| 2022-12-31 | $11.39M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $26.75M derived: sum of 2 quarters · filed 2024-03-11 | $49.16M 10-K · filed 2024-03-11 | |
| 2022-09-30 | $15.36M 10-Q · filed 2023-12-11 | $37.77M 10-Q · filed 2023-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |